Screener
Eli Lilly LLY Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 83.4%+0.8pp | 82.8%+1.1pp | 83%+1.7pp | 83%+2.1pp | 82.6%+1.9pp | |
| Net margin | 33.5%+7.6pp | 35%+12.3pp | 31.7%+8.2pp | 31%+10.5pp | 25.9%+7.0pp | |
| Returns | ||||||
| Return on equity | 102.4%+15.7pp | 107.6%+29.9pp | 101.2%+16.6pp | 96.8%+31.1pp | 86.7%+27.1pp | |
| Return on invested capital | 39.7%+10.3pp | 42%+16.7pp | 38.3%+11.8pp | 37.4%+13.8pp | 29.4%+7.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×0.0× | 0.7×+0.1× | 0.7×+0.1× | 0.6×0.0× | 0.6×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.4×+0.1× | 1.5×+0.1× | 1.6×+0.4× | 1.5×+0.3× | 1.3×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 1.6×-0.6× | 1.4×-1.1× | 1.6×-0.8× | 1.8×-0.4× | 2.2×+0.1× | |
| Net debt / EBITDA | 1.3×-0.7× | 1.1×-1.1× | 1.3×-0.9× | 1.3×-1.0× | 1.9×-0.5× | |
| Per Share | ||||||
| Book value per share | $37.91+86.7% | $34.82+98.9% | $29.51+86.9% | $26.47+68.2% | $20.31+35.4% | |
| Valuation | ||||||
| Market capitalization | $1.02T+39.5% | $821.68B+10.8% | $961.86B+38.5% | $684B-14.3% | $698.51B-14.4% | |
| Price / earnings | 38.4×-1.5× | 32.5×-34.3× | 46.6×-19.0× | 37.1×-58.2× | 50.6×-60.5× | |
| Price / sales | 12.9×+0.5× | 11.4×-3.8× | 14.8×-0.7× | 11.5×-8.0× | 13.1×-7.8× | |
| Price / book | 30.3×-0.6× | 26.3×-20.7× | 36.2×-12.4× | 28.7×-27.3× | 38.2×-21.9× | |
| EV / EBITDA | 30×-1.5× | 25.9×-24.4× | 36×-14.3× | 29.4×-40.5× | 39.2×-40.1× | |
| Dividend yield | 0.6%-0.1pp | 0.7%0.0pp | 0.6%-0.1pp | 0.8%+0.2pp | 0.7%+0.2pp |
FAQ
- Where do Eli Lilly's ratios come from?
- Every ratio is computed from Eli Lilly's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
